AI in Clinical Trials: Mapping Capital Flows & Bottlenecks

The bottleneck in clinical trial recruitment is a famously expensive problem, one that consistently drains R&D budgets and pushes back drug development timelines. So it’s no surprise that venture capital is flooding the zone, mostly targeting AI platforms that promise to find and enroll patients with the push of a button. For any of us VCs in biotech and digital health who are scrutinizing trial infrastructure, the real work is tracking this capital and figuring out which platforms have actually achieved real clinical integration. This report is our map of the field, pointing out the key players and the bottlenecks that just won’t die.

The High Stakes of Delayed Trials and the AI Opportunity

When a late-stage clinical trial gets stalled, the financial hit can run into millions of dollars per day. That’s the immediate fire, but the bigger problem is that critical therapies take that much longer to reach the patients who need them, which is why everyone’s desperate for better recruitment methods. Artificial intelligence looks like a plausible solution because it can sift through gigantic datasets, from electronic health records (EHRs) to genomic info, and match patients to trials with a precision we just couldn’t achieve before. The investment thesis is simple: AI can shorten recruitment, cut costs, and get drugs to market faster. The National Institutes of Health (NIH) is also pushing hard for more diverse participant pools, and AI-powered recruitment can actually help meet that goal by finding eligible patients in underrepresented groups, which fits perfectly with the FDA Guidance on Diversity in Clinical Trials.

Mapping Capital Flows: Model and Deep 6 AI Lead the Charge

A flood of capital is hitting AI-powered clinical trial recruitment, and two companies show the different ways investors are placing their bets.

• Model: Building a Networked Ecosystem With an enormous $203 million Series A in January 2023, Model set out to build an entire clinical trial network from the ground up, choosing to focus on connecting directly with patients and their doctors. Their plan is to create a more direct and efficient route for getting patients into trials. That mountain of cash is letting Model scale up its operations and push into more therapeutic areas, and investors are betting on their ability to become the central hub for both trial supply and patient demand. You can think of them as an AI-native company where the entire business is built around using tech to generate network effects.
• Deep 6 AI: Deep Clinical Integration with Health Systems Deep 6 AI, which Tempus AI bought in March 2025, showed how powerful deep integration within a hospital can be. Before the acquisition, Deep 6 AI worked directly with health systems, pulling patient cohorts out of messy, real-world data sources like EHRs. Their AI could scan for patients matching complex inclusion/exclusion criteria in minutes, a job that would take a human researcher weeks. The proof was in their footprint of over 750 provider site locations, which showed that hospitals were actually using the software. Deep 6 AI hospital deployment statistics Being able to show real-world evidence (RWE) of faster recruitment was a data moat that naturally attracted VC money, requiring sophisticated natural language processing (NLP) to read unstructured clinical notes, a huge technical challenge that became a big competitive advantage once they solved it.

While both companies are trying to fix the same recruitment problem, their money goes to different things. Model’s funding is for growing its network and patient-facing tools. Deep 6 AI, before it was sold, spent its cash on improving its AI engine and getting deeper into more hospital EHR systems. This points to the core question for an investor: is the long-term value going to come from the size of the network, or from the technical depth of the data extraction and matching engine?

The Clinical Site Integration Moat: A Critical Evaluation Criterion

For VCs looking at this space, the real test of a company isn’t the slickness of its AI algorithm but its ability to actually integrate with a clinical site. What’s the point of a great matching tool if it can’t get to the patient data or fit into a hospital’s existing workflow? This is where companies like the pre-acquisition Deep 6 AI had a real edge. Their partnerships with health systems weren’t just transactional sales. They embedded their tech right into how the research sites operated. Take Reify Health, another big name in trial tech. Their StudyTeam platform is everywhere for site management and tracking enrollment, but its method for identifying patients is different from the direct EHR-mining approach of a Deep 6 AI. The question every investor needs to ask is: how does this platform actually touch the patient data? Is it a separate tool that a research coordinator has to log into, or does it fundamentally change how patients are found in the first place? A deep clinical site integration creates a powerful moat with clear advantages:

• Data Access and Quality: When you’re plugged directly into the EHRs, you get real-time, complete patient data. This means less time wasted on manual chart reviews and more accurate screening, creating a data advantage that’s hard to copy.
• Workflow Efficiency: A tool that fits smoothly into the existing process gets used. A tool that adds another burden for the clinical staff gets ignored. True integration makes the AI indispensable.
• Regulatory Compliance: Platforms that are built into the health system’s IT are in a much better position to handle HIPAA and data security (like having HITRUST or SOC 2 certifications), which are absolute requirements for any hospital to even consider adoption.
• Scalability: Once you have a solid integration framework, expanding to new hospitals and new research areas becomes much faster, accelerating growth.

This “clinical site integration moat” isn’t just a tech feature. It’s a strategic position. It shows a company has cleared the huge adoption hurdles in healthcare IT and become a core part of how clinical research gets done. We see this level of integration as a strong predictor of success, impacting everything from payer penetration to the quality of published outcomes data.

Methodology and Source Note

Here’s where our analysis comes from. We’re using aggregated funding data from places like the Rock Health funding databases along with public information on platform integrations from clinicaltrials.gov and the health systems themselves. The thinking here is also shaped by our own network analysis of partnerships in the clinical trial tech world. The goal of this report is to give you a solid investment framework for looking at companies in this space, one that puts a premium on clinical validation, regulatory readiness, and how deeply a platform is integrated into the healthcare system. To sum it up, while AI in trial recruitment is an exciting story, smart investors need to look past the algorithm and at the grubby details of implementation. The companies that will win are the ones building deep, sticky integrations with clinical sites, because that’s what gives them sustained data access and gets them adopted in the real world.